Concord Biotech (BOM:543960) ROCE %: 22.11% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543960 Concord Biotech Ltd BOM:543960
68 GF Score
Price ₹1,257.00
GF Value ₹1,666.31
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Concord Biotech ROCE %?

Concord Biotech BOM:543960 +0.67% 68 ROCE % is 22.11% as of Mar. 2026. GuruFocus rates BOM:543960 with a GF Score™ of 68/100 and a GF Value™ of ₹1,666.31 (Modestly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Concord Biotech's annualized ROCE % for the quarter that ended in Mar. 2026 was 22.11%.

Concord Biotech  (BOM:543960) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Concord Biotech ROCE % Related Terms

Concord Biotech ROCE % Historical Data

* Premium members only.

The historical data trend for Concord Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Biotech ROCE % Chart

Concord Biotech Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial 21.75 26.34 28.82 29.05 17.62

Concord Biotech Quarterly Data
Mar20 Mar21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.70 12.71 18.36 18.46 22.11
BOM:543960
68GF Score
Concord Biotech Ltd BOM:543960
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Concord Biotech ROCE % Calculation

Concord Biotech's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=3449.292/( ( (20342.515 - 1840.626) + (22347.271 - 1690.771) )/ 2 )
=3449.292/( (18501.889+20656.5)/ 2 )
=3449.292/19579.1945
=17.62 %

Concord Biotech's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=4566.376/( ( (0 - 0) + (22347.271 - 1690.771) )/ 1 )
=4566.376/( ( 0 + 20656.5 )/ 1 )
=4566.376/20656.5
=22.11 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 22.11% mean?
Concord Biotech (BOM:543960) has a ROCE % of 22.11% as of Mar. 2026.
Is Concord Biotech's ROCE % too high?
Concord Biotech's current ROCE % is 22.11%. Overall, Concord Biotech has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's ROCE % compare to VRTX and REGN?
Concord Biotech's ROCE % of 22.11% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Concord Biotech's current ROCE % is 22.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,666.31, compared to a current price of ₹1,257.00 — trading 24.6% below its estimated fair value. The current ROCE % is 22.11%. Concord Biotech's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current ROCE % is 22.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Concord Biotech (BOM:543960) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued. The current stock price of ₹1,257.00 is trading 24.6% below its estimated GF Value™ of ₹1,666.31. GuruFocus considers Concord Biotech to be Modestly Undervalued.

Key valuation signals for BOM:543960:

  • ROCE %: 22.11%
  • GF Value™: ₹1,666.31 vs. price of ₹1,257.00 (24.6% below fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Concord Biotech Business Description

Other Exchanges CONCORDBIO:India
Address Iscon Cross Road, S.G. Highway, B-1601-1602, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
68GF Score

Get the complete analysis for BOM:543960

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,257.00
Price
₹1,666.31
GF Value